08:00 , Feb 24, 2014 |  BC Week In Review  |  Company News

Oxford BioMedica, Sanofi deal

The companies amended an April 2009 deal to grant Sanofi broadened worldwide rights to StarGen and UshStat for all ocular disease indications in exchange for the return to Oxford of all worldwide rights to EncorStat...
07:00 , Jul 9, 2012 |  BC Week In Review  |  Company News

Oxford BioMedica, Sanofi deal

Oxford BioMedica said Sanofi exercised its option under an April 2009 deal to acquire exclusive, worldwide rights to Oxford BioMedica's ocular disease products UshStat and StarGen . Oxford BioMedica will receive a $3 million exercise...
08:00 , Feb 1, 2010 |  BC Week In Review  |  Company News

Oxford BioMedica, Clayton Foundation for Research deal

The foundation's technology transfer arm granted Oxford BioMedica exclusive rights to IP covering a method for delivering anti-angiogenic genes to the eye using lentiviral vectors. The foundation will receive an undisclosed upfront payment and is...
07:00 , May 4, 2009 |  BC Week In Review  |  Company News

Oxford BioMedica, sanofi-aventis deal

sanofi-aventis returned to Oxford BioMedica rights to TroVax following a review of the pharma's R&D portfolio. Oxford BioMedica will receive a $16.5 million payment, including a settlement of previously committed development costs. Last year, an...